Clinical Trial Update: Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tau PET imaging with 18F-AV-1451 in individuals with MAPT mutations completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontotemporal Dementia
• Frontotemporal Lobar Degeneration
• Tauopathies

Drugs mentioned

• 18F-AV-1451 (flortaucipir)

Snippet

Sponsor: Columbia University | Conditions: Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD) | Phase 2 | Status: COMPLETED | Results posted: 2019-12-06